The rapamycin-binding domain governs substrate selectivity by the mammalian target of rapamycin.
about
Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2cdc2-cyclin B regulates eEF2 kinase activity in a cell cycle- and amino acid-dependent mannerPRAS40 is a target for mammalian target of rapamycin complex 1 and is required for signaling downstream of this complexDistinct signaling events downstream of mTOR cooperate to mediate the effects of amino acids and insulin on initiation factor 4E-binding proteins.mTOR-dependent stimulation of the association of eIF4G and eIF3 by insulin.Pushing the envelope in the mTOR pathway: the second generation of inhibitorsmTOR: from growth signal integration to cancer, diabetes and ageingRapamycin and mTOR kinase inhibitorsTor forms a dimer through an N-terminal helical solenoid with a complex topology.mTOR kinase structure, mechanism and regulationMds3 regulates morphogenesis in Candida albicans through the TOR pathwayTwo motifs in the translational repressor PHAS-I required for efficient phosphorylation by mammalian target of rapamycin and for recognition by raptorActivation of mammalian target of rapamycin (mTOR) by insulin is associated with stimulation of 4EBP1 binding to dimeric mTOR complex 1PRAS40 regulates mTORC1 kinase activity by functioning as a direct inhibitor of substrate bindingTOR signaling.Cellular response to influenza virus infection: a potential role for autophagy in CXCL10 and interferon-alpha induction.cAMP-dependent activation of mammalian target of rapamycin (mTOR) in thyroid cells. Implication in mitogenesis and activation of CDK4.Synthetic spatially graded Rac activation drives cell polarization and movement.Rapamycin is a potent inhibitor of skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate.Loss of inhibitory insulin receptor substrate-1 phosphorylation is an early event in mammalian target of rapamycin-dependent endometrial hyperplasia and carcinoma.Rapamycin inhibits cytoskeleton reorganization and cell motility by suppressing RhoA expression and activity.Stoichiometry and assembly of mTOR complexes revealed by single-molecule pulldown.Review series: TOR kinase complexes and cell migration.A retroinhibition approach reveals a tumor cell-autonomous response to rapamycin in head and neck cancerCombination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs.Analysis of 3-phosphoinositide-dependent kinase-1 signaling and function in ES cells.Stress and IGF-I differentially control cell fate through mammalian target of rapamycin (mTOR) and retinoblastoma protein (pRB)mTOR inhibitors synergize on regression, reversal of gene expression, and autophagy in hepatocellular carcinoma.A novel lead compound CM-118: antitumor activity and new insight into the molecular mechanism and combination therapy strategy in c-Met- and ALK-dependent cancers.Considerations on mTOR regulation at serine 2448: implications for muscle metabolism studies.Adenoviral proteins mimic nutrient/growth signals to activate the mTOR pathway for viral replication.Insulin receptor substrate-2 proteasomal degradation mediated by a mammalian target of rapamycin (mTOR)-induced negative feedback down-regulates protein kinase B-mediated signaling pathway in beta-cells.Insulin receptor substrate-2-dependent interleukin-4 signaling in macrophages is impaired in two models of type 2 diabetes mellitus.The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment.mTOR kinase domain phosphorylation promotes mTORC1 signaling, cell growth, and cell cycle progression.Regulation of leucine uptake by tor1+ in Schizosaccharomyces pombe is sensitive to rapamycin.In rat hepatocytes glucagon increases mammalian target of rapamycin phosphorylation on serine 2448 but antagonizes the phosphorylation of its downstream targets induced by insulin and amino acids.ANG II activates effectors of mTOR via PI3-K signaling in human coronary smooth muscle cells.Caffeine targets TOR complex I and provides evidence for a regulatory link between the FRB and kinase domains of Tor1p.Alteration of mTOR signaling occurs early in the progression of Alzheimer disease (AD): analysis of brain from subjects with pre-clinical AD, amnestic mild cognitive impairment and late-stage AD.
P2860
Q21145847-467612F9-FD56-45C8-9556-DB07465A3849Q24310776-3E8212D9-2EEC-427C-B863-91433E553974Q24316314-837151D7-6B24-41AE-BAB3-5D8533BC4E7FQ24519078-0BB53CC2-B78F-47C4-ACB3-73DC7E56CFEFQ24543920-2BD6C9E8-BDA4-4A0F-AABE-02F125EFF335Q24622222-0F452BD2-B02B-4F4E-8834-55E9893B9A1DQ24633662-78E029FF-8BCA-4709-8A3D-7FF2C59CAA1AQ24644623-A3346159-81AF-47F2-8101-8801A6EC63B6Q27323551-CDCA6F1E-3D43-4A83-993B-022D394EAF92Q27677954-363DE73B-2E39-47E7-92A0-DEE1D9DFD3F2Q27940288-5E591464-EC14-4DBF-A486-5FB51BE6F30FQ28187391-BD694B13-192A-4BA8-B3E1-30AAA4B44BE7Q28248333-DE0888FC-0709-4D0F-ABD2-CFE3D878097AQ28302887-6199D37B-BD75-4D07-BF4E-01E49B63E12BQ30312086-D1592584-6B58-49F4-9F29-2CFB93E6FE57Q30389209-1C81E72D-8958-4581-9B4B-80FDBA67C164Q30431658-5D33C253-FC48-43E9-AB3C-42BCBA5C699DQ30531107-190DB302-AD4C-4FA5-8DE7-59350614E63DQ33705425-319A7068-4DEA-456E-8C88-924D5B788D70Q33918399-2BB155F0-3361-41F3-9C96-45013A9FA05DQ34352217-1136F869-9AB5-4063-82F5-2989A622D9D1Q34752184-35725BA4-5AA6-4619-AADC-70B8B5FC6A8CQ35579442-F190A5BF-32CC-43DB-90C7-9363AB1189E6Q36237554-3AC1136F-9FA8-437E-97B9-74C8960141E1Q36854122-D098908A-9D48-42F2-AF23-1EA2F6FCE3B5Q36865347-693F8B43-20EF-4059-B24E-1638500873D5Q36940460-ED27CDEB-FDE7-4E8F-812F-C65FA465DF87Q36987718-437471AE-C4A3-4A13-A252-A7292565DF18Q39016480-4D2C0A60-F86C-437B-82A1-FCBFF479BC3BQ39144817-CC4A9F89-B731-4D7E-9E9A-70A820533779Q40445488-5CAA6D1C-4F01-496A-9FFA-6DF5F896C20AQ40493551-856F3C2E-14E7-4F82-A52D-9480D38495D7Q40559827-EB787449-E42D-4BAC-9CF9-1CB76ABAF21DQ42593305-30F64C35-00FC-45BD-9A7C-E53364F6C170Q42793655-1605B85E-1C9D-4E41-853A-EDF8383AE48DQ43275098-5CA15337-4535-4269-B79D-45249120C3CAQ45005936-643C6C4E-DAAF-4810-A970-F1E17D953EAAQ45022808-CA58B02F-C42C-4F9B-93A8-8013660AFDBCQ46016417-34FA8FB4-84F6-4C13-899C-620A16F29B22Q46778500-8A309EDC-E408-4291-93C2-CE1BE10050CC
P2860
The rapamycin-binding domain governs substrate selectivity by the mammalian target of rapamycin.
description
2002 nî lūn-bûn
@nan
2002 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
The rapamycin-binding domain g ...... mammalian target of rapamycin.
@ast
The rapamycin-binding domain g ...... mammalian target of rapamycin.
@en
type
label
The rapamycin-binding domain g ...... mammalian target of rapamycin.
@ast
The rapamycin-binding domain g ...... mammalian target of rapamycin.
@en
prefLabel
The rapamycin-binding domain g ...... mammalian target of rapamycin.
@ast
The rapamycin-binding domain g ...... mammalian target of rapamycin.
@en
P2093
P2860
P1476
The rapamycin-binding domain g ...... mammalian target of rapamycin.
@en
P2093
John C Lawrence
Kin M Choi
Lloyd P McMahon
Robert T Abraham
Tai-An Lin
P2860
P304
P356
10.1128/MCB.22.21.7428-7438.2002
P407
P577
2002-11-01T00:00:00Z